SCHEMBL12467340

SCHEMBL12467340

O=C(S)C1CCNCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL193591 0.78
Isonipecotic Acid SCHEMBL6122239 0.78 TSHR (0.94)
SCHEMBL3774341 0.77 TSHR (0.65)
Bromide SCHEMBL27312283 0.74 TSHR (0.62)
Hydrochloric Acid SCHEMBL27508984 0.74 TSHR (0.62)
Hydrochloric Acid SCHEMBL27430608 0.74 TSHR (0.62)
Isonipecotic Acid SCHEMBL2027408 0.74 TSHR (1.00)
Isonipecotic Acid SCHEMBL104297 0.74
SCHEMBL21952157 0.74
SCHEMBL1484884 0.74 TSHR (0.62)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8546435-B2 Triazole derivatives with improved receptor activity and bioavailability properties as ghrelin antagonists of growth hormone secretagogue receptors AETERNA ZENTARIS GMBH (DE) 2013-10-01 US claimed
EP-2616070-A1 NOVEL TRIAZOLE DERIVATIVES WITH IMPROVED RECEPTOR ACTIVITY AND BIOAVAILABILITY PROPERTIES AS GHRELIN ANTAGONISTS OF GROWTH HORMONE SECRETAGOGUE RECEPTORS Æterna Zentaris GmbH (DE) 2013-07-24 EP claimed
WO-2012035124-A1 NOVEL TRIAZOLE DERIVATIVES WITH IMPROVED RECEPTOR ACTIVITY AND BIOAVAILABILITY PROPERTIES AS GHRELIN ANTAGONISTS OF GROWTH HORMONE SECRETAGOGUE RECEPTORS ÆTERNA ZENTARIS GMBH (DE) 2012-03-22 WO claimed
US-8546435-B2 Triazole derivatives with improved receptor activity and bioavailability properties as ghrelin antagonists of growth hormone secretagogue receptors AETERNA ZENTARIS GMBH (DE) 2013-10-01 US disclosed